Abstract
Adverse reactions with DMSO-cryopreserved stem cell infusion are well-recognized. However, severe, life-threatening anaphylactic reactions with DMSO are very rarely described in the literature. We report here a 58-year-old female with AL amyloidosis who developed an unexpected episode of respiratory arrest a few seconds after the beginning of thawed stem cell product infusion. Fortunately, the patient was resuscitated successfully without the need for intubation. The prompt development of the reaction just a few seconds after the stem cell infusion convincingly implicates DMSO as the potential suspect. The presence of amyloid cardiomyopathy might have also contributed to this adverse event. Bone Marrow Transplantation (2000) 25, 1299–1301.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gertz MA . Amyloidosis: recognition, prognosis and conventional therapy. In: Schechter GP, Hoffman R, Schrier SL (eds) Hematology American Society of Hematology Education Program Book 1999 pp339–347
Saba N, Sutton DM, Ross HJ et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant Bone Marrow Transplant 1999 24: 853–855
Kyle RA . High-dose therapy in multiple myeloma and primary amyloidosis: an overview Semin Oncol 1999 26: 74–83
Comenzo RL . High-dose therapy for the treatment of primary systemic amyloidosis. In: Schechter GP, Hoffman R, Schrier SL (eds) Hematology American Society of Hematology Education Program Book 1999 pp347–357
Comenzo RL, Vosburgh E, Falk RH et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients Blood 1998 91: 3662–3670
Comenzo RL, Sanchorawala V, Fisher C et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light-chain) amyloidosis Br J Haematol 1999 104: 553–559
Egorin MJ, Rosen DM, Sridhara R et al. Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral blood stem cell transplants J Clin Oncol 1998 16: 610–615
Alessandrino P, Bernasconi P, Caldera D et al. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases Bone Marrow Transplant 1999 23: 533–537
Davis J, Rowley SD, Braine HG et al. Clinical toxicity of cryopreserved bone marrow graft infusion Blood 1990 75: 781–786
Rapoport AP, Rowe JM, Packman CH, Ginsberg SJ . Cardiac arrest after autologous marrow infusion Bone Marrow Transplant 1991 7: 401–403
Roy V, Veys P, Jackson F et al. Adult respiratory syndrome following autologous bone marrow transfusion Bone Marrow Transplant 1989 4: 711–712
Nishihara G, Sakemi T, Ikeda Y et al. Multiple organ failure associated with dimethylsulfoxide and hydroxyethyl starch in autologous blood stem cell transplantation Nephron 1996 72: 356–357
Miniero R, Vai S, Giacchino M et al. Severe respiratory depression after autologous bone marrow infusion Haematologica 1992 77: 98–99
Vriesendorp R, Aalders JG, Sleijfer DTh et al. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer Gynecol Oncol 1984 17: 271–276
Hameroff SR, Otto CW, Kanel J et al. Acute cardiovascular effects of dimethylsulfoxide Crit Care Med 1981 9: 855–857
Kligman AM . Topical pharmacology and toxicology of dimethylsulfoxide JAMA 1965 193: 796–804
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benekli, M., Anderson, B., Wentling, D. et al. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplant 25, 1299–1301 (2000). https://doi.org/10.1038/sj.bmt.1702452
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702452
Keywords
This article is cited by
-
The atomistic details of the ice recrystallisation inhibition activity of PVA
Nature Communications (2021)
-
A bioinspired and chemically defined alternative to dimethyl sulfoxide for the cryopreservation of human hematopoietic stem cells
Bone Marrow Transplantation (2021)
-
Cryopreservation in 95% serum with 5% DMSO maintains colony formation and chondrogenic abilities in human synovial mesenchymal stem cells
BMC Musculoskeletal Disorders (2019)
-
Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy
Bone Marrow Transplantation (2018)
-
IGF1R+ Dental Pulp Stem Cells Enhanced Neuroplasticity in Hypoxia-Ischemia Model
Molecular Neurobiology (2017)